glp-1/fgf21 agonist boehringer GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease Glucagon-like peptide-1 receptor signaling modifies

[...] Experience minimally invasive surgery at Capital Surgeons Group, combining advanced robotic and laparoscopic techniques for faster recovery and less pain

161 The results of the Phase II clinical trials of retatrutide were published in The Lancet in 2023

Lillys Oral GLP-1, Orforglipron, Demonstrated Statistically Significant Efficacy Results and a Safety Profile Consistent with Injectable GLP-1 Medicines in Successful Phase 3 Trial

Researchers reported that nearly 90% of participants who took the medication achieved an HbA1c level of 7%, the standard target for average blood glucose levels

Xie W, Gu D, Li J, Cui K, Zhang Y